FFCP PHASE1:Mm9::chr4:133654582..133654591,-: Difference between revisions
From FANTOM5_SSTAR
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
{{FFCP|EntrezGene=NA|HGNC=|MCL_coexpression_id=6|UniProt=NA|association_with_transcript=NA|description=CAGE_peak_at_chr4:133654582..133654591,-|id=chr4:133654582..133654591,-|ontology_enrichment_celltype=CL:0000945!2.79e-07!1;CL:0000236!2.79e-07!1;CL:0000826!2.79e-07!1|ontology_enrichment_celltype_v019_2=CL:0000355,2.95e-15,9|ontology_enrichment_disease=DOID:0060100!3.93e-19!3;DOID:4045!3.93e-19!3;DOID:0050686!7.51e-10!6|ontology_enrichment_disease_v019_2=DOID:0060100,6.41e-44,3;DOID:4045,6.41e-44,3;DOID:0050686,1.89e-22,6|ontology_enrichment_uberon=|ontology_enrichment_uberon_v019_2=UBERON:0001134,2.95e-15,9;UBERON:0002036,2.95e-15,9;UBERON:0002385,2.95e-15,9;UBERON:0000486,2.95e-15,9;UBERON:0007503,2.95e-15,9;UBERON:0001015,2.95e-15,9;UBERON:0002329,2.95e-15,9;UBERON:0003082,2.95e-15,9;UBERON:0003059,2.95e-15,9;UBERON:0007282,2.95e-15,9;UBERON:0004290,2.95e-15,9;UBERON:0009618,2.95e-15,9;UBERON:0000383,8.21e-14,10;UBERON:0007524,1.25e-12,11;UBERON:0003077,1.25e-12,11;UBERON:0007285,1.25e-12,11|phase1_expression=0,0,0,0,0,0,0,0,0.140788722151667,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.159992422793407,0,0,0,0,0,0,0,0,0,0,0,0,0,3.34825304589526,3.906676722619,2.09409497589519,12.3528612486513,2.73218193983378,2.42755176515577,0,0,0,0,0,0,0,0,0,0.503347818173209,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.11981512450592,0,0.127070227073065,0,0,0,0,0,0,0,0.101839363850316,0,0,0,0.130120442962704,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.284163499395593,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.139951452323658,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0|short_description=p@chr4:133654582..133654591,-}} | {{FFCP | ||
|DHSsupport=NA | |||
|DPIdataset=NA | |||
|EntrezGene=NA | |||
|HGNC= | |||
|MCL_coexpression_id=6 | |||
|TSSclassifier=NA | |||
|UniProt=NA | |||
|association_with_transcript=NA | |||
|cluster_id=chr4:133654582..133654591,- | |||
|description=CAGE_peak_at_chr4:133654582..133654591,- | |||
|id=chr4:133654582..133654591,- | |||
|ontology_enrichment_celltype=CL:0000945!2.79e-07!1;CL:0000236!2.79e-07!1;CL:0000826!2.79e-07!1 | |||
|ontology_enrichment_celltype_v019_2=CL:0000355,2.95e-15,9 | |||
|ontology_enrichment_disease=DOID:0060100!3.93e-19!3;DOID:4045!3.93e-19!3;DOID:0050686!7.51e-10!6 | |||
|ontology_enrichment_disease_v019_2=DOID:0060100,6.41e-44,3;DOID:4045,6.41e-44,3;DOID:0050686,1.89e-22,6 | |||
|ontology_enrichment_uberon= | |||
|ontology_enrichment_uberon_v019_2=UBERON:0001134,2.95e-15,9;UBERON:0002036,2.95e-15,9;UBERON:0002385,2.95e-15,9;UBERON:0000486,2.95e-15,9;UBERON:0007503,2.95e-15,9;UBERON:0001015,2.95e-15,9;UBERON:0002329,2.95e-15,9;UBERON:0003082,2.95e-15,9;UBERON:0003059,2.95e-15,9;UBERON:0007282,2.95e-15,9;UBERON:0004290,2.95e-15,9;UBERON:0009618,2.95e-15,9;UBERON:0000383,8.21e-14,10;UBERON:0007524,1.25e-12,11;UBERON:0003077,1.25e-12,11;UBERON:0007285,1.25e-12,11 | |||
|phase1_expression=0,0,0,0,0,0,0,0,0.140788722151667,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.159992422793407,0,0,0,0,0,0,0,0,0,0,0,0,0,3.34825304589526,3.906676722619,2.09409497589519,12.3528612486513,2.73218193983378,2.42755176515577,0,0,0,0,0,0,0,0,0,0.503347818173209,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.11981512450592,0,0.127070227073065,0,0,0,0,0,0,0,0.101839363850316,0,0,0,0.130120442962704,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.284163499395593,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.139951452323658,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0 | |||
|short_description=p@chr4:133654582..133654591,- | |||
}} |
Latest revision as of 22:21, 4 August 2015
Short description: | p@chr4:133654582..133654591, - |
---|---|
Species: | Mouse (Mus musculus) |
DPI dataset: | NA |
TSS-like-by-RIKEN-classifier(Yes/No): | NA |
DHS support(Yes/No): | NA |
Description: | CAGE_peak_at_chr4:133654582..133654591, - |
Coexpression cluster: | MCL_coexpression_mm9:6 |
Association with transcript: | NA |
EntrezGene: | NA |
Link to Zenbu: | ZENBU |
View on UCSC genome browser
CAGE Expression
- Click each plot point to find sample in table
Ontology-based sample term enrichment analysis<b>Summary:</b>This analysis has been performed by utilizing wilcoxon rank sum test.When the number of associated cells/tissues are > n , randomly sampled n cells/tissues are used for P value calculation with rank sum test. this process are repeated several times, and the P values are averaged on the log space <br><b>Analyst:</b> Hideya Kawaji<br><br>link to source dataset<br>data
Ontology term | p-value | n |
---|---|---|
multi-potent skeletal muscle stem cell | 2.95e-15 | 9 |
Ontology term | p-value | n |
---|---|---|
skeletal muscle tissue | 2.95e-15 | 9 |
striated muscle tissue | 2.95e-15 | 9 |
muscle tissue | 2.95e-15 | 9 |
multilaminar epithelium | 2.95e-15 | 9 |
epithelial vesicle | 2.95e-15 | 9 |
musculature | 2.95e-15 | 9 |
somite | 2.95e-15 | 9 |
myotome | 2.95e-15 | 9 |
presomitic mesoderm | 2.95e-15 | 9 |
presumptive segmental plate | 2.95e-15 | 9 |
dermomyotome | 2.95e-15 | 9 |
trunk paraxial mesoderm | 2.95e-15 | 9 |
musculature of body | 8.21e-14 | 10 |
dense mesenchyme tissue | 1.25e-12 | 11 |
paraxial mesoderm | 1.25e-12 | 11 |
presumptive paraxial mesoderm | 1.25e-12 | 11 |
Ontology term | p-value | n |
---|---|---|
musculoskeletal system cancer | 6.41e-44 | 3 |
muscle cancer | 6.41e-44 | 3 |
organ system cancer | 1.89e-22 | 6 |